ArticleAnnals of transplantation2017
Role of High-Mobility Group Box 1 (HMGB1) in Transplantation of Rat Pancreatic Islets.
Article in Annals of transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- High Mobility Group Box 1 Contributes to the Acute Rejection of Liver Allografts by Activating Dendritic Cells.Frontiers in immunology · 2021Article
- CORM-2 Pretreatment Attenuates Inflammation-mediated Islet Dysfunction.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The potential role of tissue damage factor high-mobility group box 1 (HMGB1) in islet cell transplantation is poorly understood. We investigated the role of HMGB1 in pancreatic islet cell isolation and culture in vitro and after pancreatic islet cell transplantation into diabetic nude mice in vivo. MATERIAL AND METHODS To generate damaged islets, isolated islets were treated with 1 mg/mL lipopolysaccharide (LPS). Some islets were pretreated with a neutralizing anti-HMGB1 antibody before LPS treatment to investigate the effect of HMGB1 on isolated islets damaged by LPS. Cell viability and insulin secretory function were analyzed 48 h after LPS and anti-HMGB1 antibody treatment. Streptozotocin-induced diabetes mice were injected with an anti-HMGB1 antibody 1 h prior to transplantation as a marginal islet mass. After transplantation, blood glucose levels were measured. RESULTS HMGB1 was more abundant in isolated islets than in other tissues, including pancreatic tissue. Anti-HMGB1 antibody pretreatment in LPS-treated islets improved cell viability and insulin secretory function and reduced the production of TNF-α and IL-1β. Streptozotocin-induced diabetic mice treated with an anti-HMGB1 antibody after marginal mass islet cell transplantation recovered to normal blood glucose levels more rapidly and maintained their euglycemic status compared to controls. CONCLUSIONS HMGB1 plays a significant role in early loss of transplanted islet cells. Based on these results, the development of new drugs that inhibit HMGB1 secretion could improve the efficacy and efficiency of clinical islet cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.